Amphastar Pharmaceuticals Competitors and Similar CompaniesClear all

Amphastar Pharmaceuticals's competitors and similar companies include Synthon, Vertex Pharmaceuticals and Esteve Quimica.

	Amphastar Pharmaceuticals Amphastar Pharmaceuticals is a pharmaceutical company that develops, manufactures, and markets generic and proprietary injectable, intranasal, and inhalation products.	Synthon Synthon is a pharmaceutical company that develops, manufactures, and commercializes generic medicines.	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	Esteve Quimica Esteve Quimica is a company developing, manufacturing, and marketing oral and injectable-non-sterile APIs (active pharmaceutical ingredient).
Founding Date	Founding Date 1996	Founding Date 1991	Founding Date 1989	Founding Date 1966
Type	Type Public	Type Private	Type Public	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare diabetes drug development oncology pharma
Locations	Locations Rancho Cucamonga, US HQ Nanjing Shi, CN	Locations Nijmegen, NL HQ San Lorenzo, AR Blansko, CZ San Pedro Tlaquepaque, MX Nijmegen, NL see more	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations Barcelona, ES HQ Shaoxing Shi, CN Barcelona, ES Celrà, ES
Employees	Employees 1,7619% increase	Employees 1,3301% increase	Employees 5,40013% increase	Employees 934
Valuation ($)	Valuation ($) 2.3 b	Valuation ($) N/A	Valuation ($) 121.4 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $719.9m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $12b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods $363.8m (FY, 2025)	Cost of goods N/A	Cost of goods $1.7b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $356.1m (FY, 2025)	Gross profit N/A	Gross profit $10.4b (FY, 2025)	Gross profit N/A
Operating ⚠
Products	Products 20 (Q3, 2021)	Products N/A	Products 6 (FY, 2022)	Products N/A